This is a summary. To read the whole story subscribe to BostonGlobe.com
After getting hammered for days, biotech stocks advanced. Boston-based Vertex Pharmaceuticals gained 4.3 percent, and Biogen Idec Inc., of Cambridge, rose 4 percent; its Alprolix drug for hemophilia B has just been approved. Investors had been pulling money out of biotechs and turning to less volatile stocks, such as utilities. The S&P 500 Biotechnology Index is off 10 percent this month, even with Monday’s gains. The Nasdaq Biotechnology index was up 3 percent Monday, trimming its loss for March to 11 percent.